- Home
- ADBE vs GILD Comparison
ADBE vs GILD Comparison
Compare ADBE & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADBE
- GILD
- Stock Information
- Founded
- ADBE 1982
- GILD 1987
- Country
- ADBE United States
- GILD United States
- Employees
- ADBE N/A
- GILD N/A
- Industry
- ADBE Computer Software: Prepackaged Software
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADBE Technology
- GILD Health Care
- Exchange
- ADBE Nasdaq
- GILD Nasdaq
- Market Cap
- ADBE 172.5B
- GILD 138.7B
- IPO Year
- ADBE 1986
- GILD 1992
- Fundamental
- Price
- ADBE $370.74
- GILD $116.20
- Analyst Decision
- ADBE Buy
- GILD Buy
- Analyst Count
- ADBE 22
- GILD 24
- Target Price
- ADBE $490.20
- GILD $111.91
- AVG Volume (30 Days)
- ADBE 3.5M
- GILD 6.2M
- Earning Date
- ADBE 09-11-2025
- GILD 08-07-2025
- Dividend Yield
- ADBE N/A
- GILD 2.72%
- EPS Growth
- ADBE 40.56
- GILD 1118.07
- EPS
- ADBE 15.63
- GILD 4.73
- Revenue
- ADBE $22,601,000,000.00
- GILD $28,735,000,000.00
- Revenue This Year
- ADBE $11.79
- GILD $1.69
- Revenue Next Year
- ADBE $9.46
- GILD $3.67
- P/E Ratio
- ADBE $23.72
- GILD $24.56
- Revenue Growth
- ADBE 10.63
- GILD 4.68
- 52 Week Low
- ADBE $332.01
- GILD $72.43
- 52 Week High
- ADBE $587.75
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- ADBE 43.24
- GILD 63.27
- Support Level
- ADBE $363.13
- GILD $107.75
- Resistance Level
- ADBE $376.00
- GILD $113.89
- Average True Range (ATR)
- ADBE 6.76
- GILD 2.54
- MACD
- ADBE 1.14
- GILD 0.38
- Stochastic Oscillator
- ADBE 43.13
- GILD 85.79
About ADBE Adobe Inc.
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).